Scopus Biopharma Performance
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Scopus Biopharma are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Scopus Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Scopus Biopharma is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 1.8 M | |
| Total Cashflows From Investing Activities | -1999.00 |
Scopus |
Scopus Biopharma Relative Risk vs. Return Landscape
If you would invest (100.00) in Scopus Biopharma on December 17, 2024 and sell it today you would earn a total of 100.00 from holding Scopus Biopharma or generate -100.0% return on investment over 90 days. Scopus Biopharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Scopus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Scopus Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Scopus Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Scopus Biopharma, and traders can use it to determine the average amount a Scopus Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| SCPS |
Based on monthly moving average Scopus Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Scopus Biopharma by adding Scopus Biopharma to a well-diversified portfolio.
Scopus Biopharma Fundamentals Growth
Scopus OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Scopus Biopharma, and Scopus Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Scopus OTC Stock performance.
| Return On Equity | -15.6 | ||||
| Return On Asset | -4.61 | ||||
| Current Valuation | 1.18 M | ||||
| Shares Outstanding | 21.09 M | ||||
| Price To Book | 2.42 X | ||||
| EBITDA | (26.18 M) | ||||
| Cash And Equivalents | 1.16 M | ||||
| Cash Per Share | 0.05 X | ||||
| Total Debt | 2.54 M | ||||
| Debt To Equity | 0.61 % | ||||
| Book Value Per Share | (0.26) X | ||||
| Cash Flow From Operations | (11.42 M) | ||||
| Earnings Per Share | (1.51) X | ||||
| Total Asset | 8.19 M | ||||
Things to note about Scopus Biopharma performance evaluation
Checking the ongoing alerts about Scopus Biopharma for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Scopus Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Scopus Biopharma is not yet fully synchronised with the market data | |
| Scopus Biopharma has some characteristics of a very speculative penny stock | |
| Scopus Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Scopus Biopharma currently holds 2.54 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Scopus Biopharma has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Scopus Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Scopus Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Scopus Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Scopus to invest in growth at high rates of return. When we think about Scopus Biopharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (26.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Scopus Biopharma currently holds about 1.16 M in cash with (11.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05. | |
| Roughly 51.0% of Scopus Biopharma outstanding shares are owned by corporate insiders |
- Analyzing Scopus Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Scopus Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Scopus Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Scopus Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Scopus Biopharma's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Scopus Biopharma's otc stock. These opinions can provide insight into Scopus Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |